A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Temozolomide
- drug : CDX-110 with GM-CSF
Phase: Phase 2
Ages Eligible For Study:
- Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue. - Gross total resection followed by conventional chemoradiation therapy without progression of disease.